<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Trop Med Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Trop Med Infect Dis</journal-id><journal-id journal-id-type="publisher-id">tropicalmed</journal-id><journal-title-group><journal-title>Tropical Medicine and Infectious Disease</journal-title></journal-title-group><issn pub-type="epub">2414-6366</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39998058</article-id><article-id pub-id-type="pmc">PMC11861052</article-id>
<article-id pub-id-type="doi">10.3390/tropicalmed10020054</article-id><article-id pub-id-type="publisher-id">tropicalmed-10-00054</article-id><article-categories><subj-group subj-group-type="heading"><subject>Systematic Review</subject></subj-group></article-categories><title-group><article-title>Chikungunya Fever and Rheumatoid Arthritis: A Systematic Review and Meta-Analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0528-8600</contrib-id><name><surname>Amaral</surname><given-names>Jos&#x000e9; Kennedy</given-names></name><xref rid="af1-tropicalmed-10-00054" ref-type="aff">1</xref><xref rid="c1-tropicalmed-10-00054" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Schoen</surname><given-names>Robert Taylor</given-names></name><xref rid="af2-tropicalmed-10-00054" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Weinblatt</surname><given-names>Michael E.</given-names></name><xref rid="af3-tropicalmed-10-00054" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>C&#x000e2;ndido</surname><given-names>Estelita Lima</given-names></name><xref rid="af1-tropicalmed-10-00054" ref-type="aff">1</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Prpi&#x00107;</surname><given-names>Jelena</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-tropicalmed-10-00054"><label>1</label>Postgraduate Program in Health Sciences, Faculty of Medicine, Federal University of Cariri, 284 Divino Salvador Street, Barbalha 63090-000, Cear&#x000e1;, Brazil; <email>estelita.lima@ufca.edu.br</email></aff><aff id="af2-tropicalmed-10-00054"><label>2</label>Section of Rheumatology, Allergy, and Immunology, Yale University School of Medicine, 15 York Street, New Haven, CT 06510, USA; <email>robert.schoen@yale.edu</email></aff><aff id="af3-tropicalmed-10-00054"><label>3</label>Division of Rheumatology, Inflammation and Immunity, Harvard Medical School, Brigham and Women&#x02019;s Hospital, 60 Fenwood Road, Boston, MA 02115, USA; <email>mweinblatt@bwh.harvard.edu</email></aff><author-notes><corresp id="c1-tropicalmed-10-00054"><label>*</label>Correspondence: <email>jkennedy-@hotmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>10</volume><issue>2</issue><elocation-id>54</elocation-id><history><date date-type="received"><day>14</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>04</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>06</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Chikungunya fever (CHIKF) is a re-emerging infectious disease caused by the chikungunya virus (CHIKV), transmitted primarily by Aedes mosquitoes. A significant number progress to chronic chikungunya arthritis, which shares similarities with rheumatoid arthritis (RA). Despite evidence of a link between CHIKV infection and subsequent RA development, a comprehensive analysis of the relationship between these two diseases is lacking. This study systematically analyzes the incidence of RA after CHIKV infection and its immunological mechanisms, following PRISMA guidelines with literature searches across multiple databases up to 3 September 2024. Eligible studies included retrospective and prospective designs reporting RA diagnoses after CHIKV infection. Data extraction was performed independently, and the risk of bias was assessed using appropriate tools. Sixteen studies involving 2879 patients were included, with 449 individuals diagnosed with RA following CHIKV infection, resulting in a combined incidence of 13.7% (95% CI: 6.12% to 27.87%). High heterogeneity between studies was observed (<italic toggle="yes">I</italic><sup>2</sup> = 96%), indicating variability related to diagnostic criteria and population characteristics. This review highlights the significant RA incidence after CHIKV infection, emphasizing the need for research on autoimmune mechanisms, long-term rheumatological follow-up, early diagnostic biomarkers, and CHIKV&#x02019;s long-term health impacts.</p></abstract><kwd-group><kwd>chickungunya fever</kwd><kwd>rheumatoid arthritis</kwd><kwd>joint disease</kwd><kwd>autoimmune arthritis</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-tropicalmed-10-00054"><title>1. Introduction</title><p>Chikungunya fever (CHIKF) is a mosquito-borne, viral infection that has re-emerged in global outbreaks over the past 75 years. First reported in 1952, CHIKF has since spread to over 100 countries, with over 4 million cases reported, particularly after the first case in the Americas in 2013 [<xref rid="B1-tropicalmed-10-00054" ref-type="bibr">1</xref>,<xref rid="B2-tropicalmed-10-00054" ref-type="bibr">2</xref>]. The chikungunya virus (CHIKV), a positive-sense single-stranded RNA <italic toggle="yes">Alphavirus</italic> virus is transmitted by <italic toggle="yes">Aedes mosquitoes</italic> (<italic toggle="yes">Ae. aegypti</italic> and <italic toggle="yes">Ae. albopictus</italic>) [<xref rid="B3-tropicalmed-10-00054" ref-type="bibr">3</xref>]. The disease presents with sudden fever, incapacitating polyarthritis, myalgia, rash, headache, and gastrointestinal symptoms, typically 2 to 6 days after infection [<xref rid="B4-tropicalmed-10-00054" ref-type="bibr">4</xref>]. While usually self-limiting, with recovery in 10 days, up to 40% of cases progress to a chronic phase, chronic chikungunya arthritis (CCA), characterized by persistent or deforming arthritis [<xref rid="B5-tropicalmed-10-00054" ref-type="bibr">5</xref>].</p><p>Following the global spread from Africa of the vectors of CHIKV, <italic toggle="yes">A. aegypti</italic> and <italic toggle="yes">A. albopictus</italic>, and the increase in international travel, there has been rapid geographic expansion of CHIKV infection. With the resultant increasing CCA cases, better characterization of the clinical features of CCA has been possible [<xref rid="B6-tropicalmed-10-00054" ref-type="bibr">6</xref>,<xref rid="B7-tropicalmed-10-00054" ref-type="bibr">7</xref>]. Within the clinical spectrum of CCA, some patients present as RA &#x0201c;mimics&#x0201d; with symmetric polyarthritis, morning stiffness, frequent hand involvement, and in some individuals, positive RA biomarkers. [<xref rid="B8-tropicalmed-10-00054" ref-type="bibr">8</xref>,<xref rid="B9-tropicalmed-10-00054" ref-type="bibr">9</xref>,<xref rid="B10-tropicalmed-10-00054" ref-type="bibr">10</xref>]. Not infrequently, these individuals meet ACR (American College of Rheumatology)/EULAR (European Alliance of Associations for Rheumatology) classification criteria for RA [<xref rid="B11-tropicalmed-10-00054" ref-type="bibr">11</xref>,<xref rid="B12-tropicalmed-10-00054" ref-type="bibr">12</xref>] Whether CCA mimics RA or whether CHIKV infection increases the risk of developing ongoing RA is still a subject of debate.</p><p>The similarities between CCA and RA are pathological as well as clinical [<xref rid="B5-tropicalmed-10-00054" ref-type="bibr">5</xref>,<xref rid="B10-tropicalmed-10-00054" ref-type="bibr">10</xref>,<xref rid="B11-tropicalmed-10-00054" ref-type="bibr">11</xref>,<xref rid="B13-tropicalmed-10-00054" ref-type="bibr">13</xref>]. RA is a systemic inflammatory disease of multifactorial etiology characterized by chronic and progressive synovitis [<xref rid="B9-tropicalmed-10-00054" ref-type="bibr">9</xref>,<xref rid="B10-tropicalmed-10-00054" ref-type="bibr">10</xref>,<xref rid="B11-tropicalmed-10-00054" ref-type="bibr">11</xref>]. RA pathogenesis involves interactions between genetic, environmental, and immunological factors, resulting in dysregulated immune responses and chronic inflammation, damaging joints and other organs [<xref rid="B10-tropicalmed-10-00054" ref-type="bibr">10</xref>]. Immunophenotyping of peripheral blood mononuclear cells in RA and CCA reveals a common inflammatory profile, suggesting shared immunological mechanisms. Viral persistence in joints, detection of viral genetic material in the synovium, and activation of innate and adaptive immune responses are mechanisms proposed to explain CCA pathogenesis. Autoimmunity induced by molecular mimicry or virus-induced tissue damage has also been considered [<xref rid="B8-tropicalmed-10-00054" ref-type="bibr">8</xref>,<xref rid="B11-tropicalmed-10-00054" ref-type="bibr">11</xref>].</p><p>There has long been interest in whether RA is linked to viral infection [<xref rid="B12-tropicalmed-10-00054" ref-type="bibr">12</xref>]. For CCA, there is a fundamental pathogenic question as to whether the arthritis phase results from persistent viral infection or a post-viral inflammatory process [<xref rid="B13-tropicalmed-10-00054" ref-type="bibr">13</xref>,<xref rid="B14-tropicalmed-10-00054" ref-type="bibr">14</xref>]. There is also a question as to whether CCA patients benefit from a disease-modifying treatment strategy, borrowed from the treatment of RA [<xref rid="B11-tropicalmed-10-00054" ref-type="bibr">11</xref>]. For these multiple reasons, we conducted a systematic review and meta-analysis to evaluate current evidence on the development of RA following CHIKV infection. We believe that the increasingly available data justify further investigation of pathogenic similarities between these two diseases and support CCA therapeutic strategies informed by RA treatment.</p></sec><sec id="sec2-tropicalmed-10-00054"><title>2. Materials and Methods</title><p>The study protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO) (protocol CRD42024585798). This study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [<xref rid="B15-tropicalmed-10-00054" ref-type="bibr">15</xref>] guidelines to address the following question: &#x0201c;What are the characteristics and incidence of rheumatoid arthritis development in patients after chikungunya virus infection?&#x0201d;</p><sec id="sec2dot1-tropicalmed-10-00054"><title>2.1. Information Sources</title><p>We systematically searched PubMed, Cochrane Library, Scielo, LILACS, Web of Science, and Scopus for relevant literature published until 3 September 2024. We also incorporated studies found through manual searches using Google Scholar, gray literature, and reference lists. Articles in English, Spanish, or Portuguese were included.</p></sec><sec id="sec2dot2-tropicalmed-10-00054"><title>2.2. Eligibility Criteria</title><p>Retrospective and prospective studies, randomized controlled trials, and case series reporting diagnosis of RA after CHIKV infection, with clinically and laboratory-confirmed testing for anti-CHIKV-specific immunoglobulin M (for acute cases) or immunoglobulin G (post-exposure) detected by enzyme-linked immunosorbent assay (ELISA) or RNA virus by reverse-transcriptase polymerase chain reaction were included. Studies were excluded if they did not include laboratory confirmation of CHIKV, did not follow the ACR-EULAR classification criteria, or presented insufficient data for analysis. We excluded from this systematic review: letters to the editor, editorials, review articles, commentaries, preclinical trials, and papers without relevant data.</p></sec><sec id="sec2dot3-tropicalmed-10-00054"><title>2.3. Search Strategy</title><p>Search terms included combinations of free-text and MeSH or Emtree terms for CHIK and RA, including (&#x0201c;Chikungunya virus&#x0201d; (MeSH) OR &#x0201c;Chikungunya fever&#x0201d; (MeSH) OR &#x0201c;CHIKV&#x0201d; OR &#x0201c;Chikungunya infection&#x0201d; OR &#x0201c;Chikungunya&#x0201d; OR &#x0201c;CHIK&#x0201d; OR &#x0201c;CHIKV&#x0201d;) AND (&#x0201c;Arthritis, Rheumatoid&#x0201d; (MeSH) OR &#x0201c;Rheumatoid arthritis&#x0201d; OR &#x0201c;Autoimmune arthritis&#x0201d; OR &#x0201c;RA&#x0201d;). Information about the databases used, search dates, search methods, and the number of studies retrieved is provided in the <xref rid="app1-tropicalmed-10-00054" ref-type="app">Supplementary Materials (Table S1)</xref>.</p></sec><sec id="sec2dot4-tropicalmed-10-00054"><title>2.4. Selection Process</title><p>Two independent reviewers (J.K.A. and R.T.S.) screened titles and abstracts based on the eligibility criteria. Studies with uncertain relevance were included to ensure all potentially relevant work was considered. Disagreements were resolved through discussion, with a third reviewer involved if necessary. The same process was applied to full-text reviews, with further evaluation of studies with unclear relevance at the abstract stage.</p></sec><sec id="sec2dot5-tropicalmed-10-00054"><title>2.5. Data Collection Process</title><p>Independent reviewers (J.K.A. and R.T.S.) extracted data using a standardized form (<xref rid="app1-tropicalmed-10-00054" ref-type="app">Table S2</xref>). Afterward, a second reviewer independently verified the data to ensure all relevant information was included. Any discrepancies were resolved through discussion, with a third reviewer involved if necessary. The form captured details such as author, publication year, country, study design, patient demographics, type of chikungunya diagnosis, number of RA cases, comparators, evaluation measures, symptoms, clinical progression, and study results.</p></sec><sec id="sec2dot6-tropicalmed-10-00054"><title>2.6. Data Items</title><p>Data were collected on the following outcomes: the incidence of RA, defined by the percentage of patients who developed RA after CHIKV infection, as diagnosed by the authors of the included studies using standard clinical and laboratory criteria; the clinical and demographic characteristics of patients, including mean age (&#x000b1;standard deviation), sex (male/female), country of origin, and type of chikungunya diagnosis (acute or post-exposure), as determined by the detection of anti-CHIKV IgM or IgG antibodies or viral RNA by PCR; the measures used to assess RA, such as clinical examinations, laboratory tests, and established diagnostic criteria; the clinical evolution of patients, including descriptions of symptoms, duration of arthritis, clinical progression of the disease, and response to specific treatments, when applicable; and other relevant outcomes, including any other relevant findings associated with the development of RA following CHIK infection, as reported in the included studies.</p></sec><sec id="sec2dot7-tropicalmed-10-00054"><title>2.7. Study Risk of Bias Assessment</title><p>The risk of bias in the included studies was assessed using tools appropriate to each study design, focusing on those that confirmed CHIKV infection through serological tests (IgM/IgG anti-CHIKV) or other validated methods. Two reviewers independently evaluated the risk of bias using the Newcastle&#x02013;Ottawa Scale (NOS) for cohort studies, the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for case series and observational studies, and the RoB 2.0 tool for randomized controlled trials [<xref rid="B16-tropicalmed-10-00054" ref-type="bibr">16</xref>,<xref rid="B17-tropicalmed-10-00054" ref-type="bibr">17</xref>,<xref rid="B18-tropicalmed-10-00054" ref-type="bibr">18</xref>,<xref rid="B19-tropicalmed-10-00054" ref-type="bibr">19</xref>].</p></sec></sec><sec sec-type="results" id="sec3-tropicalmed-10-00054"><title>3. Results</title><sec id="sec3dot1-tropicalmed-10-00054"><title>3.1. Study Selection</title><p>A total of 4392 studies were retrieved from the database searches. After exclusion by reading the titles and/or abstracts and duplicates, only 46 articles were selected for full reading. Sixteen studies met the eligibility criteria and were included in the systematic review (<xref rid="tropicalmed-10-00054-f001" ref-type="fig">Figure 1</xref>).</p></sec><sec id="sec3dot2-tropicalmed-10-00054"><title>3.2. Study Characteristics</title><p>The studies included in this systematic review were conducted in diverse geographical and epidemiological settings, reflecting the wide geographic distribution of CHIKV infection and its rheumatological consequences. Two cross-sectional studies were conducted in Brazil [<xref rid="B20-tropicalmed-10-00054" ref-type="bibr">20</xref>] and Colombia [<xref rid="B21-tropicalmed-10-00054" ref-type="bibr">21</xref>]. Nine cohort studies included research from Bangladesh [<xref rid="B22-tropicalmed-10-00054" ref-type="bibr">22</xref>], the United States [<xref rid="B23-tropicalmed-10-00054" ref-type="bibr">23</xref>], France [<xref rid="B24-tropicalmed-10-00054" ref-type="bibr">24</xref>], India [<xref rid="B25-tropicalmed-10-00054" ref-type="bibr">25</xref>,<xref rid="B26-tropicalmed-10-00054" ref-type="bibr">26</xref>,<xref rid="B27-tropicalmed-10-00054" ref-type="bibr">27</xref>], Colombia [<xref rid="B28-tropicalmed-10-00054" ref-type="bibr">28</xref>,<xref rid="B29-tropicalmed-10-00054" ref-type="bibr">29</xref>], and Reunion Island [<xref rid="B30-tropicalmed-10-00054" ref-type="bibr">30</xref>]. Four case series studies were conducted in the United States [<xref rid="B31-tropicalmed-10-00054" ref-type="bibr">31</xref>], France [<xref rid="B32-tropicalmed-10-00054" ref-type="bibr">32</xref>], Reunion Island [<xref rid="B33-tropicalmed-10-00054" ref-type="bibr">33</xref>], and Brazil [<xref rid="B34-tropicalmed-10-00054" ref-type="bibr">34</xref>]. The randomized controlled trial was conducted in India [<xref rid="B35-tropicalmed-10-00054" ref-type="bibr">35</xref>].</p></sec><sec id="sec3dot3-tropicalmed-10-00054"><title>3.3. Risk of Bias in Studies</title><sec id="sec3dot3dot1-tropicalmed-10-00054"><title>3.3.1. Cross-Sectional and Case Series Studies</title><p>Among the cross-sectional studies, both Hayd et al. [<xref rid="B20-tropicalmed-10-00054" ref-type="bibr">20</xref>] and Tritsch et al. [<xref rid="B21-tropicalmed-10-00054" ref-type="bibr">21</xref>] were rated as having a moderate risk of bias. These studies showed limitations in controlling for potential confounding factors that could affect the validity of their findings. Similarly, among the case series studies, there was variable bias risk. While some case series, such as Javelle et al. [<xref rid="B33-tropicalmed-10-00054" ref-type="bibr">33</xref>], were rated with low risk of bias due to their clear inclusion criteria and consistent measurement of outcomes, others, including Miner et al. [<xref rid="B31-tropicalmed-10-00054" ref-type="bibr">31</xref>], Bouquillard and Combe [<xref rid="B32-tropicalmed-10-00054" ref-type="bibr">32</xref>], and Amaral et al. [<xref rid="B34-tropicalmed-10-00054" ref-type="bibr">34</xref>], were assessed as having a moderate risk of bias due to concerns related to participant selection and the handling of incomplete data.</p></sec><sec id="sec3dot3dot2-tropicalmed-10-00054"><title>3.3.2. Cohort Studies</title><p>A significant proportion of the cohort studies (n = 7 of 9) were rated with low risk of bias. These studies, such as Pollett et al. [<xref rid="B23-tropicalmed-10-00054" ref-type="bibr">23</xref>], Manimunda et al. [<xref rid="B25-tropicalmed-10-00054" ref-type="bibr">25</xref>], Segura-Charry et al. [<xref rid="B28-tropicalmed-10-00054" ref-type="bibr">28</xref>], Rodriguez-Morales et al. [<xref rid="B29-tropicalmed-10-00054" ref-type="bibr">29</xref>], Paul et al. [<xref rid="B26-tropicalmed-10-00054" ref-type="bibr">26</xref>], Mathew et al. [<xref rid="B27-tropicalmed-10-00054" ref-type="bibr">27</xref>], and Guillot et al. [<xref rid="B30-tropicalmed-10-00054" ref-type="bibr">30</xref>], adhered to rigorous methodological standards, including valid and reliable measurement of exposures and outcomes, identification and control of confounding factors, and sufficient follow-up duration to capture relevant outcomes.</p><p>Two cohort studies were rated with a moderate risk of bias. Hossain et al. [<xref rid="B22-tropicalmed-10-00054" ref-type="bibr">22</xref>] and Bouquillard et al. [<xref rid="B24-tropicalmed-10-00054" ref-type="bibr">24</xref>] had incomplete follow-up and inadequate handling of confounding factors that could introduce bias into their findings.</p></sec><sec id="sec3dot3dot3-tropicalmed-10-00054"><title>3.3.3. Randomized Controlled Trials</title><p>The randomized controlled trial by Ravindran and Alias [<xref rid="B35-tropicalmed-10-00054" ref-type="bibr">35</xref>] was rated with some bias concerns using the RoB 2.0 tool. The study was an open-label design, raising potential bias in the measurement of subjective outcomes. Although the trial demonstrated strength in areas like randomization and handling of missing data, the open-label nature could have influenced participant behavior or reporting, leading to &#x0201c;some concerns&#x0201d; about the overall risk of bias.</p><p>The details are reported in the <xref rid="app1-tropicalmed-10-00054" ref-type="app">Supplementary Materials</xref>.</p></sec></sec><sec id="sec3dot4-tropicalmed-10-00054"><title>3.4. Results of Individual Studies</title><p>A total of 2879 patients infected by CHIKV were found in the included studies, with 449 diagnosed with RA. The studies differed by location and methods but consistently identified patients meeting RA diagnostic criteria after infection. Common symptoms included persistent joint pain, morning stiffness, polyarthralgia, joint swelling, and auto-antibodies such as rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP). Severe cases showed bone erosions, synovitis, and required advanced therapies like tumor necrosis factor (TNF) blockers and other biologics.</p><p>For example, Segura-Charry et al. [<xref rid="B28-tropicalmed-10-00054" ref-type="bibr">28</xref>] reported that 87 of 410 patients developed RA, with many requiring biologics therapy due to disease severity. In Guillot et al. [<xref rid="B30-tropicalmed-10-00054" ref-type="bibr">30</xref>], 40 of 159 patients had persistent symptoms up to 13 years post infection, highlighting the chronic nature of RA after CHIKV. Bouquillard and Combe [<xref rid="B32-tropicalmed-10-00054" ref-type="bibr">32</xref>] and Javelle et al. [<xref rid="B33-tropicalmed-10-00054" ref-type="bibr">33</xref>] demonstrated the effectiveness of methotrexate (MTX) in alleviating symptoms and slowing disease progression. Ravindran and Alias found combination therapy with MTX, sulfasalazine, and hydroxychloroquine (HCQ) more effective than HCQ monotherapy in reducing RA activity after CHIKV [<xref rid="B35-tropicalmed-10-00054" ref-type="bibr">35</xref>].</p><p>See <xref rid="tropicalmed-10-00054-t001" ref-type="table">Table 1</xref> for details on each study, including diagnosed cases and clinical characteristics.</p></sec><sec id="sec3dot5-tropicalmed-10-00054"><title>3.5. Quality Assessment</title><p>Most of the studies included in the systematic review demonstrated good methodological quality, with low or moderate risk of bias. The rigorous application of the NOS, JBI, and RoB 2.0 bias assessment tools allowed for a clear identification of the strengths and limitations of each study.</p></sec><sec id="sec3dot6-tropicalmed-10-00054"><title>3.6. Meta-Analysis</title><p>The combined proportion of patients who developed RA after CHIKV infection was 13.7% (IC 95%: 6.12% to 27.87%), based on the random effects model, due to high heterogeneity among studies (<italic toggle="yes">I</italic><sup>2</sup> = 96%, <italic toggle="yes">Q</italic> = 373.00, <italic toggle="yes">p</italic> &#x0003c; 0.0001). The graph in <xref rid="tropicalmed-10-00054-f002" ref-type="fig">Figure 2</xref> presents the individual estimates of RA proportion for each study, as well as the combined estimate obtained through the random effects model. After excluding cross-sectional studies and case series from the meta-analysis, heterogeneity reduced from 96% to 76.8% (<italic toggle="yes">Q</italic> = 33.4969, <italic toggle="yes">p</italic> &#x0003c; 0.0001), indicating better homogeneity among the remaining studies.</p><p>The analysis only with cohort studies classified as having low risk of bias resulted in an incidence of rheumatoid arthritis of 17.7% (95% CI: 4.2&#x02013;31.3%). Although heterogeneity decreased compared to the full meta-analysis, it still remained high (<italic toggle="yes">I</italic><sup>2</sup> = 81.07%).</p><p>The certainty of the evidence was assessed using the GRADE approach, considering risk of bias, inconsistency, imprecision, publication bias, and applicability of the results. For the incidence of RA post CHIKV, the certainty was considered moderate, downgraded due to inconsistency (<italic toggle="yes">I</italic><sup>2</sup> = 96%, IC 95%: 6.12&#x02013;27.87%).</p><p>A forest plot showing the proportions of patients who developed rheumatoid arthritis after chikungunya infection in each study is included in the meta-analysis. The diamond at the bottom represents the combined proportion with a 95% confidence interval. The random effects model was used due to the high heterogeneity observed.</p></sec></sec><sec sec-type="discussion" id="sec4-tropicalmed-10-00054"><title>4. Discussion</title><p>This systematic review is, to our knowledge, the first to explore the relationship between CHIKV infection and the subsequent development of RA. Despite the heterogeneity of RA incidence among these studies, the meta-analysis suggests that a significant proportion of patients develop RA after CHIKV infection. However, the observed variability indicates that factors such as population characteristics, diagnostic methods, and follow-up duration may influence results. Our systematic review was restricted to studies that assessed RA as recognized in ACR-EULAR classification criteria [<xref rid="B11-tropicalmed-10-00054" ref-type="bibr">11</xref>]. Rodr&#x000ed;guez-Morales et al. conducted a more general review in which they classified RA as part of a group called &#x0201c;post-CHIK chronic arthritis&#x0201d; that also included post-viral or nonspecific arthritis and seronegative spondylitis, finding a prevalence of 13.66%. However, they did not specifically evaluate RA separately [<xref rid="B36-tropicalmed-10-00054" ref-type="bibr">36</xref>].</p><p>Despite the variation in follow-up time among the studies in this review, we suggest that a longer period of time may be necessary to identify RA patients after CHIKV infection, as demonstrated in the study by Guillot et al. [<xref rid="B30-tropicalmed-10-00054" ref-type="bibr">30</xref>]. We acknowledge that the absence of a standardized observation period among the studies may have influenced the variability of the estimates, representing a limitation of this analysis.</p><p>Many CCA patients develop RA symptoms that clinically resemble classic RA, such as persistent joint pain, morning stiffness, polyarthralgia, and joint swelling [<xref rid="B37-tropicalmed-10-00054" ref-type="bibr">37</xref>,<xref rid="B38-tropicalmed-10-00054" ref-type="bibr">38</xref>,<xref rid="B39-tropicalmed-10-00054" ref-type="bibr">39</xref>]. But is this RA or an RA &#x0201c;mimic&#x0201d;? Many of these patients had severe disease, with joint erosions and synovitis, suggesting that CHIKV may cause the same inflammatory processes associated with RA, as described in another review [<xref rid="B5-tropicalmed-10-00054" ref-type="bibr">5</xref>]. The presence of auto-antibodies, such as RF and anti-CCP, also indicates that CHIKV may trigger autoimmunity, clinically indistinguishable from RA in non-CHIKV-infected individuals [<xref rid="B8-tropicalmed-10-00054" ref-type="bibr">8</xref>].</p><p>These clinical features are consistent with the known pathogenesis of post-CHIKV infection RA [<xref rid="B14-tropicalmed-10-00054" ref-type="bibr">14</xref>]. Viral persistence and molecular mimicry are possible mechanisms for the development of RA after CHIKV infection. Bouquillard et al. demonstrated that viral components can remain in synovial tissue long after acute infection, leading to chronic inflammation [<xref rid="B32-tropicalmed-10-00054" ref-type="bibr">32</xref>]. Additionally, Miner et al. [<xref rid="B31-tropicalmed-10-00054" ref-type="bibr">31</xref>] and Guillot et al. [<xref rid="B30-tropicalmed-10-00054" ref-type="bibr">30</xref>] report that CHIKV-induced arthritis shares immunological characteristics with idiopathic RA.</p><p>The efficacy of treatments for RA, such as MTX and biologic therapy in patients with CHIKV-induced arthritis has been documented in studies by Bouquillard and Combe [<xref rid="B32-tropicalmed-10-00054" ref-type="bibr">32</xref>] and Javelle et al. [<xref rid="B33-tropicalmed-10-00054" ref-type="bibr">33</xref>]. In these cohorts, patients with more severe manifestations required more aggressive treatment, such as TNF inhibitors, reflecting the chronic and refractory nature of post-CHIKV RA. These treatments significantly improved outcomes, reducing pain and disease activity. However, a recent clinical trial review did not demonstrate additional benefits of these drugs compared to anti-inflammatories or placebo [<xref rid="B40-tropicalmed-10-00054" ref-type="bibr">40</xref>].</p><p>Our review and meta-analysis included mostly observational studies, which may represent an important limitation because this type of study is more susceptible to selection bias and residual confounding. This may contribute to the high heterogeneity observed in the results (reduction of <italic toggle="yes">I</italic><sup>2</sup> from 96% to 76.8%), and the incidence estimate, which went from 16.2% to 12.4%. However, due to the nature of the topic investigated, there is a limited availability of randomized controlled trials that could reduce these biases. Another limitation that should be mentioned is the variation in sample sizes (between 10 and 437 patients), which may influence the precision of the pooled estimates.</p><p>Future studies should prioritize the standardization of diagnostic criteria and the long-term follow-up of specific subgroups in order to more accurately clarify the risk factors for the development of RA after CHIKV infection. Moreover, research focused on early interventions is essential to reduce the impact of this disease. Given the chronic and debilitating nature of CHIKV-associated RA, it is crucial to explore the mechanisms of autoimmunity triggered by the virus. For this, longitudinal studies with well-defined cohorts are fundamental, allowing not only for a better understanding of disease progression but also for the identification of biomarkers that facilitate early diagnosis. Finally, clinical trials are indispensable to assess the long-term efficacy and safety of biological therapies and combined treatments, offering new perspectives for therapeutic management.</p></sec><sec sec-type="conclusions" id="sec5-tropicalmed-10-00054"><title>5. Conclusions</title><p>This systematic review and meta-analysis revealed that a significant proportion of patients infected with CHIKV develop RA, with a combined estimate of 13.7% (95% CI: 6.12% to 27.87%). However, the high heterogeneity between the studies (<italic toggle="yes">I</italic><sup>2</sup> = 96%) indicates considerable variability in the findings, suggesting that factors such as differences in diagnostic criteria, study populations, and follow-up durations may have influenced the results.</p><p>These findings reinforce the need for long-term rheumatological follow-up in patients who have survived CHIKV infection, especially in endemic regions. The identification of autoimmune mechanisms associated with viral infection and the development of biomarkers for early diagnosis are important areas for future investigations.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-tropicalmed-10-00054"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/tropicalmed10020054/s1">https://www.mdpi.com/article/10.3390/tropicalmed10020054/s1</uri>, Table S1: Details of risk of bias assessments based on the Newcastle&#x02013;Ottawa Scale (NOS) for cohort studies; Table S2: Details of risk of bias assessments based on The Joanna Briggs Institute Critical Appraisal tool for cross-sectional analysis studies; Table S3: Details of risk of bias assessments based on The Joanna Briggs Institute Critical Appraisal tool for cohort studies; Table S4: Details of risk of bias assessments based on The Joanna Briggs Institute Critical Appraisal tool for case series; Table S5: Details of risk of bias assessments based on RoB 2.0 tool for randomized trials.</p><supplementary-material id="tropicalmed-10-00054-s001" position="float" content-type="local-data"><media xlink:href="tropicalmed-10-00054-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, J.K.A.; methodology, J.K.A.; software, J.K.A.; validation, J.K.A., R.T.S., M.E.W. and E.L.C.; formal analysis, J.K.A.; investigation, J.K.A. and R.T.S.; resources, J.K.A. and M.E.W.; data curation, J.K.A.; writing&#x02014;original draft preparation, J.K.A. and R.T.S.; writing&#x02014;review and editing, J.K.A., R.T.S., M.E.W. and E.L.C.; visualization, J.K.A.; supervision, R.T.S. and E.L.C.; project administration, J.K.A. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in this study are included in the article and <xref rid="app1-tropicalmed-10-00054" ref-type="app">Supplementary Materials</xref>. Further inquiries can be directed to the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-tropicalmed-10-00054"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Costa</surname><given-names>L.B.</given-names></name>
<name><surname>Barreto</surname><given-names>F.K.A.</given-names></name>
<name><surname>Barreto</surname><given-names>M.C.A.</given-names></name>
<name><surname>dos Santos</surname><given-names>T.H.P.</given-names></name>
<name><surname>Andrade</surname><given-names>M.d.M.O.d.</given-names></name>
<name><surname>Farias</surname><given-names>L.A.B.G.</given-names></name>
<name><surname>de Freitas</surname><given-names>A.R.R.</given-names></name>
<name><surname>Martinez</surname><given-names>M.J.</given-names></name>
<name><surname>Cavalcanti</surname><given-names>L.P.d.G.</given-names></name>
</person-group><article-title>Epidemiology and Economic Burden of Chikungunya: A Systematic Literature Review</article-title><source>Trop. Med. Infect. Dis.</source><year>2023</year><volume>8</volume><elocation-id>301</elocation-id><pub-id pub-id-type="doi">10.3390/tropicalmed8060301</pub-id><pub-id pub-id-type="pmid">37368719</pub-id>
</element-citation></ref><ref id="B2-tropicalmed-10-00054"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferreira de Almeida</surname><given-names>I.</given-names></name>
<name><surname>Code&#x000e7;o</surname><given-names>C.T.</given-names></name>
<name><surname>Lana</surname><given-names>R.M.</given-names></name>
<name><surname>Bastos</surname><given-names>L.S.</given-names></name>
<name><surname>Oliveira</surname><given-names>S.d.S.</given-names></name>
<name><surname>Ferreira</surname><given-names>D.A.d.C.</given-names></name>
<name><surname>Godinho</surname><given-names>V.B.</given-names></name>
<name><surname>Riback</surname><given-names>T.I.S.</given-names></name>
<name><surname>Cruz</surname><given-names>O.G.</given-names></name>
<name><surname>Coelho</surname><given-names>F.C.</given-names></name>
</person-group><article-title>The Expansion of Chikungunya in Brazil</article-title><source>Lancet Reg. Health Am.</source><year>2023</year><volume>25</volume><fpage>100571</fpage><pub-id pub-id-type="doi">10.1016/j.lana.2023.100571</pub-id><pub-id pub-id-type="pmid">37638140</pub-id>
</element-citation></ref><ref id="B3-tropicalmed-10-00054"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bartholomeeusen</surname><given-names>K.</given-names></name>
<name><surname>Daniel</surname><given-names>M.</given-names></name>
<name><surname>LaBeaud</surname><given-names>D.A.</given-names></name>
<name><surname>Gasque</surname><given-names>P.</given-names></name>
<name><surname>Peeling</surname><given-names>R.W.</given-names></name>
<name><surname>Stephenson</surname><given-names>K.E.</given-names></name>
<name><surname>Ng</surname><given-names>L.F.P.</given-names></name>
<name><surname>Ari&#x000eb;n</surname><given-names>K.K.</given-names></name>
</person-group><article-title>Chikungunya Fever</article-title><source>Nat. Rev. Dis. Primers</source><year>2023</year><volume>9</volume><fpage>17</fpage><comment>Erratum in <italic toggle="yes">Nat. Rev. Dis. Primers</italic>
<bold>2023</bold>, <italic toggle="yes">9</italic>, 26</comment><pub-id pub-id-type="doi">10.1038/s41572-023-00429-2</pub-id><pub-id pub-id-type="pmid">37024497</pub-id>
</element-citation></ref><ref id="B4-tropicalmed-10-00054"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mourad</surname><given-names>O.</given-names></name>
<name><surname>Makhani</surname><given-names>L.</given-names></name>
<name><surname>Chen</surname><given-names>L.H.</given-names></name>
</person-group><article-title>Chikungunya: An Emerging Public Health Concern</article-title><source>Curr. Infect. Dis. Rep.</source><year>2022</year><volume>24</volume><fpage>217</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1007/s11908-022-00789-y</pub-id><pub-id pub-id-type="pmid">36415286</pub-id>
</element-citation></ref><ref id="B5-tropicalmed-10-00054"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Amaral</surname><given-names>J.K.</given-names></name>
<name><surname>Taylor</surname><given-names>P.C.</given-names></name>
<name><surname>Schoen</surname><given-names>R.T.</given-names></name>
</person-group><article-title>Bone Erosions and Joint Damage Caused by Chikungunya Virus: A Systematic Review</article-title><source>Rev. Soc. Bras. Med. Trop.</source><year>2024</year><volume>57</volume><fpage>e00404</fpage><pub-id pub-id-type="doi">10.1590/0037-8682-0433-2023</pub-id><pub-id pub-id-type="pmid">38597523</pub-id>
</element-citation></ref><ref id="B6-tropicalmed-10-00054"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wahid</surname><given-names>B.</given-names></name>
<name><surname>Ali</surname><given-names>A.</given-names></name>
<name><surname>Rafique</surname><given-names>S.</given-names></name>
<name><surname>Idrees</surname><given-names>M.</given-names></name>
</person-group><article-title>Global Expansion of Chikungunya Virus: Mapping the 64-Year History</article-title><source>Int. J. Infect. Dis.</source><year>2017</year><volume>58</volume><fpage>69</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2017.03.006</pub-id><pub-id pub-id-type="pmid">28288924</pub-id>
</element-citation></ref><ref id="B7-tropicalmed-10-00054"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Charrel</surname><given-names>R.N.</given-names></name>
<name><surname>de Lamballerie</surname><given-names>X.</given-names></name>
<name><surname>Raoult</surname><given-names>D.</given-names></name>
</person-group><article-title>Chikungunya Outbreaks&#x02014;The Globalization of Vector-Borne Diseases</article-title><source>N. Engl. J. Med.</source><year>2007</year><volume>356</volume><fpage>769</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1056/NEJMp078013</pub-id><pub-id pub-id-type="pmid">17314335</pub-id>
</element-citation></ref><ref id="B8-tropicalmed-10-00054"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bezerra</surname><given-names>L.A.</given-names></name>
<name><surname>da Silva Bastos</surname><given-names>Y.C.</given-names></name>
<name><surname>Gon&#x000e7;ales</surname><given-names>J.P.</given-names></name>
<name><surname>Silva J&#x000fa;nior</surname><given-names>J.V.J.</given-names></name>
<name><surname>De Lorena</surname><given-names>V.M.B.</given-names></name>
<name><surname>Duarte</surname><given-names>A.L.B.P.</given-names></name>
<name><surname>Marques</surname><given-names>C.D.L.</given-names></name>
<name><surname>Co&#x000ea;lho</surname><given-names>M.R.C.D.</given-names></name>
</person-group><article-title>Synergism between Chikungunya Virus Infection and Rheumatoid Arthritis on Cytokine Levels: Clinical Implications?</article-title><source>Braz. J. Microbiol.</source><year>2023</year><volume>54</volume><fpage>885</fpage><lpage>890</lpage><pub-id pub-id-type="doi">10.1007/s42770-023-00976-6</pub-id><pub-id pub-id-type="pmid">37118056</pub-id>
</element-citation></ref><ref id="B9-tropicalmed-10-00054"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alivernini</surname><given-names>S.</given-names></name>
<name><surname>Firestein</surname><given-names>G.S.</given-names></name>
<name><surname>McInnes</surname><given-names>I.B.</given-names></name>
</person-group><article-title>The Pathogenesis of Rheumatoid Arthritis</article-title><source>Immunity</source><year>2022</year><volume>55</volume><fpage>2255</fpage><lpage>2270</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2022.11.009</pub-id><pub-id pub-id-type="pmid">36516818</pub-id>
</element-citation></ref><ref id="B10-tropicalmed-10-00054"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scherer</surname><given-names>H.U.</given-names></name>
<name><surname>H&#x000e4;upl</surname><given-names>T.</given-names></name>
<name><surname>Burmester</surname><given-names>G.R.</given-names></name>
</person-group><article-title>The Etiology of Rheumatoid Arthritis</article-title><source>J. Autoimmun.</source><year>2020</year><volume>110</volume><fpage>102400</fpage><pub-id pub-id-type="doi">10.1016/j.jaut.2019.102400</pub-id><pub-id pub-id-type="pmid">31980337</pub-id>
</element-citation></ref><ref id="B11-tropicalmed-10-00054"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aletaha</surname><given-names>D.</given-names></name>
<name><surname>Neogi</surname><given-names>T.</given-names></name>
<name><surname>Silman</surname><given-names>A.J.</given-names></name>
<name><surname>Funovits</surname><given-names>J.</given-names></name>
<name><surname>Felson</surname><given-names>D.T.</given-names></name>
<name><surname>Bingham</surname><given-names>C.O.</given-names><suffix>3rd</suffix></name>
<name><surname>Birnbaum</surname><given-names>N.S.</given-names></name>
<name><surname>Burmester</surname><given-names>G.R.</given-names></name>
<name><surname>Bykerk</surname><given-names>V.P.</given-names></name>
<name><surname>Cohen</surname><given-names>M.D.</given-names></name>
<etal/>
</person-group><article-title>2010 Rheumatoid Arthritis Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative</article-title><source>Arthritis Rheum.</source><year>2010</year><volume>62</volume><fpage>2569</fpage><lpage>2581</lpage><pub-id pub-id-type="doi">10.1002/art.27584</pub-id><pub-id pub-id-type="pmid">20872595</pub-id>
</element-citation></ref><ref id="B12-tropicalmed-10-00054"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Amaral</surname><given-names>J.K.</given-names></name>
<name><surname>Bingham</surname><given-names>C.O.</given-names><suffix>3rd</suffix></name>
<name><surname>Taylor</surname><given-names>P.C.</given-names></name>
<name><surname>Vil&#x000e1;</surname><given-names>L.M.</given-names></name>
<name><surname>Weinblatt</surname><given-names>M.E.</given-names></name>
<name><surname>Schoen</surname><given-names>R.T.</given-names></name>
</person-group><article-title>Pathogenesis of Chronic Chikungunya Arthritis: Resemblances and Links with Rheumatoid Arthritis</article-title><source>Travel Med. Infect. Dis.</source><year>2023</year><volume>52</volume><fpage>102534</fpage><pub-id pub-id-type="doi">10.1016/j.tmaid.2022.102534</pub-id><pub-id pub-id-type="pmid">36549417</pub-id>
</element-citation></ref><ref id="B13-tropicalmed-10-00054"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kudaeva</surname><given-names>F.M.</given-names></name>
<name><surname>Speechley</surname><given-names>M.R.</given-names></name>
<name><surname>Pope</surname><given-names>J.E.</given-names></name>
</person-group><article-title>A Systematic Review of Viral Exposures as a Risk for Rheumatoid Arthritis</article-title><source>Semin. Arthritis Rheum.</source><year>2019</year><volume>48</volume><fpage>587</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1016/j.semarthrit.2018.03.011</pub-id><pub-id pub-id-type="pmid">29747994</pub-id>
</element-citation></ref><ref id="B14-tropicalmed-10-00054"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kril</surname><given-names>V.</given-names></name>
<name><surname>A&#x000ef;qui-Reboul-Paviet</surname><given-names>O.</given-names></name>
<name><surname>Briant</surname><given-names>L.</given-names></name>
<name><surname>Amara</surname><given-names>A.</given-names></name>
</person-group><article-title>New Insights into Chikungunya Virus Infection and Pathogenesis</article-title><source>Annu. Rev. Virol.</source><year>2021</year><volume>8</volume><fpage>327</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1146/annurev-virology-091919-102021</pub-id><pub-id pub-id-type="pmid">34255544</pub-id>
</element-citation></ref><ref id="B15-tropicalmed-10-00054"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Page</surname><given-names>M.J.</given-names></name>
<name><surname>McKenzie</surname><given-names>J.E.</given-names></name>
<name><surname>Bossuyt</surname><given-names>P.M.</given-names></name>
<name><surname>Boutron</surname><given-names>I.</given-names></name>
<name><surname>Hoffmann</surname><given-names>T.C.</given-names></name>
<name><surname>Mulrow</surname><given-names>C.D.</given-names></name>
<name><surname>Shamseer</surname><given-names>L.</given-names></name>
<name><surname>Tetzlaff</surname><given-names>J.M.</given-names></name>
<name><surname>Akl</surname><given-names>E.A.</given-names></name>
<name><surname>Brennan</surname><given-names>S.E.</given-names></name>
<etal/>
</person-group><article-title>The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews</article-title><source>BMJ</source><year>2021</year><volume>372</volume><fpage>n71</fpage><pub-id pub-id-type="doi">10.1136/bmj.n71</pub-id><pub-id pub-id-type="pmid">33782057</pub-id>
</element-citation></ref><ref id="B16-tropicalmed-10-00054"><label>16.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<name><surname>Wells</surname><given-names>G.A.</given-names></name>
<name><surname>Shea</surname><given-names>B.</given-names></name>
<name><surname>O&#x02019;Connell</surname><given-names>D.A.</given-names></name>
<name><surname>Peterson</surname><given-names>J.</given-names></name>
<name><surname>Welch</surname><given-names>V.</given-names></name>
<name><surname>Losos</surname><given-names>M.</given-names></name>
<name><surname>Tugwell</surname><given-names>P.</given-names></name>
<collab>The Ottawa Hospital Research Institute</collab>
</person-group><article-title>The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses</article-title><year>2009</year><comment>Available online: <ext-link xlink:href="http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp" ext-link-type="uri">http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-14">(accessed on 14 September 2024)</date-in-citation></element-citation></ref><ref id="B17-tropicalmed-10-00054"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Munn</surname><given-names>Z.</given-names></name>
<name><surname>Barker</surname><given-names>T.H.</given-names></name>
<name><surname>Moola</surname><given-names>S.</given-names></name>
<name><surname>Tufanaru</surname><given-names>C.</given-names></name>
<name><surname>Stern</surname><given-names>C.</given-names></name>
<name><surname>McArthur</surname><given-names>A.</given-names></name>
<name><surname>Stephenson</surname><given-names>M.</given-names></name>
<name><surname>Aromataris</surname><given-names>E.</given-names></name>
</person-group><article-title>Methodological Quality of Case Series Studies: An Introduction to the JBI Critical Appraisal Tool</article-title><source>JBI Evid. Synth.</source><year>2020</year><volume>18</volume><fpage>2127</fpage><lpage>2133</lpage><pub-id pub-id-type="doi">10.11124/JBISRIR-D-19-00099</pub-id><pub-id pub-id-type="pmid">33038125</pub-id>
</element-citation></ref><ref id="B18-tropicalmed-10-00054"><label>18.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Moola</surname><given-names>S.</given-names></name>
<name><surname>Munn</surname><given-names>Z.</given-names></name>
<name><surname>Tufanaru</surname><given-names>C.</given-names></name>
<name><surname>Aromataris</surname><given-names>E.</given-names></name>
<name><surname>Sears</surname><given-names>K.</given-names></name>
<name><surname>Sfetcu</surname><given-names>R.</given-names></name>
<name><surname>Currie</surname><given-names>M.</given-names></name>
<name><surname>Qureshi</surname><given-names>R.</given-names></name>
<name><surname>Mattis</surname><given-names>P.</given-names></name>
<name><surname>Lisy</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Chapter 7: Systematic Reviews of Etiology and Risk</article-title><source>JBI Manual for Evidence Synthesis</source><person-group person-group-type="editor">
<name><surname>Aromataris</surname><given-names>E.</given-names></name>
<name><surname>Munn</surname><given-names>Z.</given-names></name>
</person-group><publisher-name>JBI</publisher-name><publisher-loc>Adelaide, Australia</publisher-loc><year>2020</year><comment>Available online: <ext-link xlink:href="https://synthesismanual.jbi.global" ext-link-type="uri">https://synthesismanual.jbi.global</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-14">(accessed on 14 September 2024)</date-in-citation></element-citation></ref><ref id="B19-tropicalmed-10-00054"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sterne</surname><given-names>J.A.C.</given-names></name>
<name><surname>Savovi&#x00107;</surname><given-names>J.</given-names></name>
<name><surname>Page</surname><given-names>M.J.</given-names></name>
<name><surname>Elbers</surname><given-names>R.G.</given-names></name>
<name><surname>Blencowe</surname><given-names>N.S.</given-names></name>
<name><surname>Boutron</surname><given-names>I.</given-names></name>
<name><surname>Cates</surname><given-names>C.J.</given-names></name>
<name><surname>Cheng</surname><given-names>H.-Y.</given-names></name>
<name><surname>Corbett</surname><given-names>M.S.</given-names></name>
<name><surname>Eldridge</surname><given-names>S.M.</given-names></name>
<etal/>
</person-group><article-title>RoB 2: A Revised Tool for Assessing Risk of Bias in Randomised Trials</article-title><source>BMJ</source><year>2019</year><volume>366</volume><fpage>l4898</fpage><pub-id pub-id-type="doi">10.1136/bmj.l4898</pub-id><pub-id pub-id-type="pmid">31462531</pub-id>
</element-citation></ref><ref id="B20-tropicalmed-10-00054"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hayd</surname><given-names>R.L.N.</given-names></name>
<name><surname>Moreno</surname><given-names>M.R.</given-names></name>
<name><surname>Naveca</surname><given-names>F.</given-names></name>
<name><surname>Amdur</surname><given-names>R.</given-names></name>
<name><surname>Suchowiecki</surname><given-names>K.</given-names></name>
<name><surname>Watson</surname><given-names>H.</given-names></name>
<name><surname>Firestein</surname><given-names>G.S.</given-names></name>
<name><surname>Simon</surname><given-names>G.</given-names></name>
<name><surname>Chang</surname><given-names>A.Y.</given-names></name>
</person-group><article-title>Persistent Chikungunya Arthritis in Roraima, Brazil</article-title><source>Clin. Rheumatol.</source><year>2020</year><volume>39</volume><fpage>2781</fpage><lpage>2787</lpage><pub-id pub-id-type="doi">10.1007/s10067-020-05011-9</pub-id><pub-id pub-id-type="pmid">32170487</pub-id>
</element-citation></ref><ref id="B21-tropicalmed-10-00054"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tritsch</surname><given-names>S.R.</given-names></name>
<name><surname>Encinales</surname><given-names>L.</given-names></name>
<name><surname>Pacheco</surname><given-names>N.</given-names></name>
<name><surname>Cadena</surname><given-names>A.</given-names></name>
<name><surname>Cure</surname><given-names>C.</given-names></name>
<name><surname>McMahon</surname><given-names>E.</given-names></name>
<name><surname>Watson</surname><given-names>H.</given-names></name>
<name><surname>Ramirez</surname><given-names>A.P.</given-names></name>
<name><surname>Mendoza</surname><given-names>A.R.</given-names></name>
<name><surname>Li</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Chronic Joint Pain 3 Years After Chikungunya Virus Infection Largely Characterized by Relapsing-Remitting Symptoms</article-title><source>J. Rheumatol.</source><year>2020</year><volume>47</volume><fpage>1267</fpage><lpage>1274</lpage><pub-id pub-id-type="doi">10.3899/jrheum.190162</pub-id><pub-id pub-id-type="pmid">31263071</pub-id>
</element-citation></ref><ref id="B22-tropicalmed-10-00054"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hossain</surname><given-names>S.</given-names></name>
<name><surname>Choudhury</surname><given-names>M.R.</given-names></name>
<name><surname>Islam</surname><given-names>M.A.</given-names></name>
<name><surname>Hassan</surname><given-names>M.</given-names></name>
<name><surname>Yeasmin</surname><given-names>S.</given-names></name>
<name><surname>Hossain</surname><given-names>F.</given-names></name>
<name><surname>Zaman</surname><given-names>M.M.</given-names></name>
</person-group><article-title>Post-Chikungunya Arthritis: A Longitudinal Study in a Tertiary Care Hospital in Bangladesh</article-title><source>Trop. Med. Health</source><year>2022</year><volume>50</volume><fpage>21</fpage><pub-id pub-id-type="doi">10.1186/s41182-022-00412-9</pub-id><pub-id pub-id-type="pmid">35260197</pub-id>
</element-citation></ref><ref id="B23-tropicalmed-10-00054"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pollett</surname><given-names>S.</given-names></name>
<name><surname>Hsieh</surname><given-names>H.C.</given-names></name>
<name><surname>Lu</surname><given-names>D.</given-names></name>
<name><surname>Grance</surname><given-names>M.</given-names></name>
<name><surname>Richard</surname><given-names>S.</given-names></name>
<name><surname>Nowak</surname><given-names>G.</given-names></name>
<name><surname>Lanteri</surname><given-names>C.</given-names></name>
<name><surname>Tribble</surname><given-names>D.</given-names></name>
<name><surname>Burgess</surname><given-names>T.</given-names></name>
</person-group><article-title>The Risk and Risk Factors of Chikungunya Virus Infection and Rheumatological Sequelae in a Cohort of U.S. Military Health System Beneficiaries: Implications for the Vaccine Era</article-title><source>PLoS Negl. Trop. Dis.</source><year>2024</year><volume>18</volume><elocation-id>e0011810</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0011810</pub-id><pub-id pub-id-type="pmid">39102422</pub-id>
</element-citation></ref><ref id="B24-tropicalmed-10-00054"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bouquillard</surname><given-names>E.</given-names></name>
<name><surname>Fianu</surname><given-names>A.</given-names></name>
<name><surname>Bangil</surname><given-names>M.</given-names></name>
<name><surname>Charlette</surname><given-names>N.</given-names></name>
<name><surname>Rib&#x000e9;ra</surname><given-names>A.</given-names></name>
<name><surname>Michault</surname><given-names>A.</given-names></name>
<name><surname>Favier</surname><given-names>F.</given-names></name>
<name><surname>Simon</surname><given-names>F.</given-names></name>
<name><surname>Flipo</surname><given-names>R.-M.</given-names></name>
</person-group><article-title>Rheumatic Manifestations Associated with Chikungunya Virus Infection: A Study of 307 Patients with 32-Month Follow-Up (RHUMATOCHIK Study)</article-title><source>Jt. Bone Spine</source><year>2018</year><volume>85</volume><fpage>207</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1016/j.jbspin.2017.01.014</pub-id><pub-id pub-id-type="pmid">28238882</pub-id>
</element-citation></ref><ref id="B25-tropicalmed-10-00054"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Manimunda</surname><given-names>S.P.</given-names></name>
<name><surname>Vijayachari</surname><given-names>P.</given-names></name>
<name><surname>Uppoor</surname><given-names>R.</given-names></name>
<name><surname>Sugunan</surname><given-names>A.P.</given-names></name>
<name><surname>Singh</surname><given-names>S.S.</given-names></name>
<name><surname>Rai</surname><given-names>S.K.</given-names></name>
<name><surname>Sudeep</surname><given-names>A.B.</given-names></name>
<name><surname>Muruganandam</surname><given-names>N.</given-names></name>
<name><surname>Chaitanya</surname><given-names>I.K.</given-names></name>
<name><surname>Guruprasad</surname><given-names>D.R.</given-names></name>
</person-group><article-title>Clinical Progression of Chikungunya Fever During Acute and Chronic Arthritic Stages and the Changes in Joint Morphology as Revealed by Imaging</article-title><source>Trans. R. Soc. Trop. Med. Hyg.</source><year>2010</year><volume>104</volume><fpage>392</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1016/j.trstmh.2010.01.011</pub-id><pub-id pub-id-type="pmid">20171708</pub-id>
</element-citation></ref><ref id="B26-tropicalmed-10-00054"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Paul</surname><given-names>B.J.</given-names></name>
<name><surname>Pannarkady</surname><given-names>G.</given-names></name>
<name><surname>Moni</surname><given-names>S.P.</given-names></name>
<name><surname>Thachil</surname><given-names>E.J.</given-names></name>
</person-group><article-title>Clinical Profile and Long-Term Sequelae of Chikungunya Fever</article-title><source>Indian J. Rheumatol.</source><year>2011</year><volume>6</volume><fpage>12</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/S0973-3698(11)60024-1</pub-id></element-citation></ref><ref id="B27-tropicalmed-10-00054"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mathew</surname><given-names>A.J.</given-names></name>
<name><surname>Goyal</surname><given-names>V.</given-names></name>
<name><surname>George</surname><given-names>E.</given-names></name>
<name><surname>Thekkemuriyil</surname><given-names>D.V.</given-names></name>
<name><surname>Jayakumar</surname><given-names>B.</given-names></name>
<name><surname>Chopra</surname><given-names>A.</given-names></name>
<collab>Trivandrum COPCORD Study Group</collab>
</person-group><article-title>Rheumatic-Musculoskeletal Pain and Disorders in a Na&#x000ef;ve Group of Individuals 15 Months Following a Chikungunya Viral Epidemic in South India: A Population-Based Observational Study</article-title><source>Int. J. Clin. Pract.</source><year>2011</year><volume>65</volume><fpage>1306</fpage><lpage>1312</lpage><pub-id pub-id-type="doi">10.1111/j.1742-1241.2011.02792.x</pub-id><pub-id pub-id-type="pmid">22093538</pub-id>
</element-citation></ref><ref id="B28-tropicalmed-10-00054"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Segura-Charry</surname><given-names>J.S.</given-names></name>
<name><surname>Parada-Martinez</surname><given-names>M.A.</given-names></name>
<name><surname>Segura-Puello</surname><given-names>H.R.</given-names></name>
<name><surname>Mu&#x000f1;oz-Forero</surname><given-names>D.M.</given-names></name>
<name><surname>Nieto-Mosquera</surname><given-names>D.L.</given-names></name>
<name><surname>Villamil-Ballesteros</surname><given-names>A.C.</given-names></name>
<name><surname>Cort&#x000e9;s-Mu&#x000f1;oz</surname><given-names>A.J.</given-names></name>
</person-group><article-title>Musculoskeletal Disorders Due to Chikungunya Virus: A Real Experience in a Rheumatology Department in Neiva, Huila</article-title><source>Reumatol. Clin.</source><year>2021</year><volume>17</volume><fpage>456</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1016/j.reuma.2020.04.002</pub-id><pub-id pub-id-type="pmid">34625148</pub-id>
</element-citation></ref><ref id="B29-tropicalmed-10-00054"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rodriguez-Morales</surname><given-names>A.J.</given-names></name>
<name><surname>Gil-Restrepo</surname><given-names>A.F.</given-names></name>
<name><surname>Ram&#x000ed;rez-Jaramillo</surname><given-names>V.</given-names></name>
<name><surname>Montoya-Arias</surname><given-names>C.P.</given-names></name>
<name><surname>Acevedo-Mendoza</surname><given-names>W.F.</given-names></name>
<name><surname>Bedoya-Arias</surname><given-names>J.E.</given-names></name>
<name><surname>Chica-Quintero</surname><given-names>L.A.</given-names></name>
<name><surname>Murillo-Garc&#x000ed;a</surname><given-names>D.R.</given-names></name>
<name><surname>Garc&#x000ed;a-Robledo</surname><given-names>J.E.</given-names></name>
<name><surname>Castrill&#x000f3;n-Spitia</surname><given-names>J.D.</given-names></name>
<etal/>
</person-group><article-title>Post-Chikungunya Chronic Inflammatory Rheumatism: Results from a Retrospective Follow-Up Study of 283 Adult and Child Cases in La Virginia, Risaralda, Colombia</article-title><source>F1000Res.</source><year>2016</year><volume>5</volume><fpage>360</fpage><pub-id pub-id-type="doi">10.12688/f1000research.8235.1</pub-id><pub-id pub-id-type="pmid">27081477</pub-id>
</element-citation></ref><ref id="B30-tropicalmed-10-00054"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guillot</surname><given-names>X.</given-names></name>
<name><surname>Ribera</surname><given-names>A.</given-names></name>
<name><surname>Gasque</surname><given-names>P.</given-names></name>
</person-group><article-title>Chikungunya-Induced Arthritis in Reunion Island: A Long-Term Observational Follow-Up Study Showing Frequently Persistent Joint Symptoms, Some Cases of Persistent Chikungunya Immunoglobulin M Positivity, and no Anticyclic Citrullinated Peptide Seroconversion After 13 Years</article-title><source>J. Infect. Dis.</source><year>2020</year><volume>222</volume><fpage>1740</fpage><lpage>1744</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiaa388</pub-id><pub-id pub-id-type="pmid">32428203</pub-id>
</element-citation></ref><ref id="B31-tropicalmed-10-00054"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Miner</surname><given-names>J.J.</given-names></name>
<name><surname>Aw-Yeang</surname><given-names>H.X.</given-names></name>
<name><surname>Fox</surname><given-names>J.M.</given-names></name>
<name><surname>Taffner</surname><given-names>S.</given-names></name>
<name><surname>Malkova</surname><given-names>O.N.</given-names></name>
<name><surname>Oh</surname><given-names>S.T.</given-names></name>
<name><surname>Kim</surname><given-names>A.H.J.</given-names></name>
<name><surname>Diamond</surname><given-names>M.S.</given-names></name>
<name><surname>Lenschow</surname><given-names>D.J.</given-names></name>
<name><surname>Yokoyama</surname><given-names>W.M.</given-names></name>
</person-group><article-title>Chikungunya Viral Arthritis in the United States: A Mimic of Seronegative Rheumatoid Arthritis</article-title><source>Arthritis Rheumatol.</source><year>2015</year><volume>67</volume><fpage>1214</fpage><lpage>1220</lpage><pub-id pub-id-type="doi">10.1002/art.39027</pub-id><pub-id pub-id-type="pmid">25605621</pub-id>
</element-citation></ref><ref id="B32-tropicalmed-10-00054"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bouquillard</surname><given-names>E.</given-names></name>
<name><surname>Combe</surname><given-names>B.</given-names></name>
</person-group><article-title>A Report of 21 Cases of Rheumatoid Arthritis Following Chikungunya Fever: A Mean Follow-Up of Two Years</article-title><source>Jt. Bone Spine</source><year>2009</year><volume>76</volume><fpage>654</fpage><lpage>657</lpage><pub-id pub-id-type="doi">10.1016/j.jbspin.2009.08.005</pub-id><pub-id pub-id-type="pmid">19945329</pub-id>
</element-citation></ref><ref id="B33-tropicalmed-10-00054"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Javelle</surname><given-names>E.</given-names></name>
<name><surname>Ribera</surname><given-names>A.</given-names></name>
<name><surname>Degasne</surname><given-names>I.</given-names></name>
<name><surname>Ga&#x000fc;z&#x000e8;re</surname><given-names>B.A.</given-names></name>
<name><surname>Marimoutou</surname><given-names>C.</given-names></name>
<name><surname>Simon</surname><given-names>F.</given-names></name>
</person-group><article-title>Specific Management of Post-Chikungunya Rheumatic Disorders: A Retrospective Study of 159 Cases in Reunion Island from 2006&#x02013;2012</article-title><source>PLoS Negl. Trop. Dis.</source><year>2015</year><volume>9</volume><elocation-id>e0003603</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0003603</pub-id><pub-id pub-id-type="pmid">25760632</pub-id>
</element-citation></ref><ref id="B34-tropicalmed-10-00054"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Amaral</surname><given-names>J.K.</given-names></name>
<name><surname>Bingham</surname><given-names>C.O.</given-names><suffix>3rd</suffix></name>
<name><surname>Schoen</surname><given-names>R.T.</given-names></name>
</person-group><article-title>Successful Methotrexate Treatment of Chronic Chikungunya Arthritis</article-title><source>J. Clin. Rheumatol.</source><year>2020</year><volume>26</volume><fpage>119</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1097/RHU.0000000000000943</pub-id><pub-id pub-id-type="pmid">30520824</pub-id>
</element-citation></ref><ref id="B35-tropicalmed-10-00054"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ravindran</surname><given-names>V.</given-names></name>
<name><surname>Alias</surname><given-names>G.</given-names></name>
</person-group><article-title>Efficacy of Combination DMARD Therapy vs. Hydroxychloroquine Monotherapy in Chronic Persistent Chikungunya Arthritis: A 24-Week Randomized Controlled Open Label Study</article-title><source>Clin. Rheumatol.</source><year>2017</year><volume>36</volume><fpage>1335</fpage><lpage>1340</lpage><pub-id pub-id-type="doi">10.1007/s10067-016-3429-0</pub-id><pub-id pub-id-type="pmid">27699657</pub-id>
</element-citation></ref><ref id="B36-tropicalmed-10-00054"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rodr&#x000ed;guez-Morales</surname><given-names>A.J.</given-names></name>
<name><surname>Cardona-Ospina</surname><given-names>J.A.</given-names></name>
<name><surname>Urbano-Garz&#x000f3;n</surname><given-names>S.F.</given-names></name>
<name><surname>Hurtado-Zapata</surname><given-names>S.</given-names></name>
</person-group><article-title>Prevalence of Post-Chikungunya Infection Chronic Inflammatory Arthritis: A Systematic Review and Meta-Analysis</article-title><source>Arthritis Care Res.</source><year>2016</year><volume>68</volume><fpage>1849</fpage><lpage>1858</lpage><pub-id pub-id-type="doi">10.1002/acr.22900</pub-id></element-citation></ref><ref id="B37-tropicalmed-10-00054"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Edington</surname><given-names>F.</given-names></name>
<name><surname>Varj&#x000e3;o</surname><given-names>D.</given-names></name>
<name><surname>Melo</surname><given-names>P.</given-names></name>
</person-group><article-title>Incidence of Articular Pain and Arthritis After Chikungunya Fever in the Americas: A Systematic Review of the Literature and Meta-Analysis</article-title><source>Joint Bone Spine</source><year>2018</year><volume>85</volume><fpage>669</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1016/j.jbspin.2018.03.019</pub-id><pub-id pub-id-type="pmid">30053609</pub-id>
</element-citation></ref><ref id="B38-tropicalmed-10-00054"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rama</surname><given-names>K.</given-names></name>
<name><surname>de Roo</surname><given-names>A.M.</given-names></name>
<name><surname>Louwsma</surname><given-names>T.</given-names></name>
<name><surname>Hofstra</surname><given-names>H.S.</given-names></name>
<name><surname>Amaral</surname><given-names>G.S.G.D.</given-names></name>
<name><surname>Vondeling</surname><given-names>G.T.</given-names></name>
<name><surname>Postma</surname><given-names>M.J.</given-names></name>
<name><surname>Freriks</surname><given-names>R.D.</given-names></name>
</person-group><article-title>Clinical Outcomes of Chikungunya: A Systematic Literature Review and Meta-Analysis</article-title><source>PLoS Negl. Trop. Dis.</source><year>2024</year><volume>18</volume><elocation-id>e0012254</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0012254</pub-id><pub-id pub-id-type="pmid">38848443</pub-id>
</element-citation></ref><ref id="B39-tropicalmed-10-00054"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Paix&#x000e3;o</surname><given-names>E.S.</given-names></name>
<name><surname>Rodrigues</surname><given-names>L.C.</given-names></name>
<name><surname>Costa</surname><given-names>M.D.C.N.</given-names></name>
<name><surname>Itaparica</surname><given-names>M.</given-names></name>
<name><surname>Barreto</surname><given-names>F.</given-names></name>
<name><surname>G&#x000e9;rardin</surname><given-names>P.</given-names></name>
<name><surname>Teixeira</surname><given-names>M.G.</given-names></name>
</person-group><article-title>Chikungunya Chronic Disease: A Systematic Review and Meta-Analysis</article-title><source>Trans. R. Soc. Trop. Med. Hyg.</source><year>2018</year><volume>112</volume><fpage>301</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1093/trstmh/try063</pub-id><pub-id pub-id-type="pmid">30007303</pub-id>
</element-citation></ref><ref id="B40-tropicalmed-10-00054"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rodrigo</surname><given-names>C.</given-names></name>
<name><surname>Herath</surname><given-names>T.</given-names></name>
<name><surname>Wickramarachchi</surname><given-names>U.</given-names></name>
<name><surname>Fernando</surname><given-names>D.</given-names></name>
<name><surname>Rajapakse</surname><given-names>S.</given-names></name>
</person-group><article-title>Treatment of Chikungunya-Associated Joint Pain: A Systematic Review of Controlled Clinical Trials</article-title><source>Trans. R. Soc. Trop. Med. Hyg.</source><year>2022</year><volume>116</volume><fpage>889</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.1093/trstmh/trac045</pub-id><pub-id pub-id-type="pmid">35666998</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="tropicalmed-10-00054-f001"><label>Figure 1</label><caption><p>PRISMA flow diagram of search results. PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses.</p></caption><graphic xlink:href="tropicalmed-10-00054-g001" position="float"/></fig><fig position="float" id="tropicalmed-10-00054-f002"><label>Figure 2</label><caption><p>Forest plot of proportion of rheumatoid arthritis in patients after chikungunya infection [<xref rid="B20-tropicalmed-10-00054" ref-type="bibr">20</xref>,<xref rid="B21-tropicalmed-10-00054" ref-type="bibr">21</xref>,<xref rid="B22-tropicalmed-10-00054" ref-type="bibr">22</xref>,<xref rid="B23-tropicalmed-10-00054" ref-type="bibr">23</xref>,<xref rid="B24-tropicalmed-10-00054" ref-type="bibr">24</xref>,<xref rid="B25-tropicalmed-10-00054" ref-type="bibr">25</xref>,<xref rid="B26-tropicalmed-10-00054" ref-type="bibr">26</xref>,<xref rid="B27-tropicalmed-10-00054" ref-type="bibr">27</xref>,<xref rid="B28-tropicalmed-10-00054" ref-type="bibr">28</xref>,<xref rid="B29-tropicalmed-10-00054" ref-type="bibr">29</xref>,<xref rid="B30-tropicalmed-10-00054" ref-type="bibr">30</xref>,<xref rid="B31-tropicalmed-10-00054" ref-type="bibr">31</xref>,<xref rid="B32-tropicalmed-10-00054" ref-type="bibr">32</xref>,<xref rid="B33-tropicalmed-10-00054" ref-type="bibr">33</xref>,<xref rid="B34-tropicalmed-10-00054" ref-type="bibr">34</xref>,<xref rid="B35-tropicalmed-10-00054" ref-type="bibr">35</xref>].</p></caption><graphic xlink:href="tropicalmed-10-00054-g002" position="float"/></fig><table-wrap position="float" id="tropicalmed-10-00054-t001"><object-id pub-id-type="pii">tropicalmed-10-00054-t001_Table 1</object-id><label>Table 1</label><caption><p>Characteristics and outcomes of studies evaluating rheumatoid arthritis following chikungunya virus infection.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Author, Year and Country</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Design</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">N&#x000ba; Patients, N&#x000ba; Male/FemaleAge Mean &#x000b1; SD or Median (Years)</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Chikungunya Diagnosis Type</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">N&#x000ba; Rheumatoid Arthritis Diagnosed Patients</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Comparators</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Evaluation Measure</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Description of Symptoms and Clinical Evolution</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Results</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Risk of Bias</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hayd et al., 2020 [<xref rid="B20-tropicalmed-10-00054" ref-type="bibr">20</xref>], Brazil</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional analysis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">160 patients: 40 with chronic arthritis (CHIKV), 40 without arthritis (CHIKV exposed), 40 with RA (controls), 40 healthy controls; Predominantly female; Age: 48.6 &#x000b1; 11.5 (CHIKV arthritis), 43.9 &#x000b1; 16.3 (CHIKV without arthritis), 51 &#x000b1; 13.4 (RA Controls), 31.9 &#x000b1; 11.7 (Healthy controls)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RT-qPCR confirmed CHIKV cases</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 patients </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rheumatoid arthritis controls, CHIKV exposed without arthritis, healthy controls</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DAS28, EQ-5D-5L, MSQ</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Initial symptoms: fever, joint pain, headache, myalgia. Chronic symptoms included persistent arthritis affecting fingers, knees, wrists, toes, and ankles, with some patients experiencing relapsing-remitting joint pain.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Over 2 years post-infection, moderate arthritis severity was reported, significantly affecting the quality of life due to pain</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Moderate <sup>a</sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Hossain et al., 2022 [<xref rid="B22-tropicalmed-10-00054" ref-type="bibr">22</xref>], Bangladesh</td><td align="left" valign="middle" rowspan="1" colspan="1">Retrospective observational cohort study</td><td align="left" valign="middle" rowspan="1" colspan="1">143 patients: 73 male/70 female, age: 43.3 &#x000b1; 11.5</td><td align="left" valign="middle" rowspan="1" colspan="1">RT-PCR or IgM/IgG positive</td><td align="left" valign="middle" rowspan="1" colspan="1">7 patients </td><td align="left" valign="middle" rowspan="1" colspan="1">Patients with pre-existing arthritis (RA, SpA, OA), patients without arthritis</td><td align="left" valign="middle" rowspan="1" colspan="1">HAQ, RF, ACPA, X-ray sacroiliac joint, Ultrasound (musculoskeletal)</td><td align="left" valign="middle" rowspan="1" colspan="1">Initial symptoms included fever, polyarthralgia, symmetrical joint involvement; chronic phase symptoms included persistent mono/oligoarthritis, polyarthritis, RA, SpA.</td><td align="left" valign="middle" rowspan="1" colspan="1">At 1-year follow-up, 41.9% of patients had post-chikungunya chronic inflammatory rheumatism (pCHIK-CIR). Risk factors included female gender, positive IgG, and moderate to severe functional disability.</td><td align="left" valign="middle" rowspan="1" colspan="1">Moderate <sup>b</sup></td></tr><tr><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Miner et al., 2015 [<xref rid="B31-tropicalmed-10-00054" ref-type="bibr">31</xref>], USA</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Retrospective case series</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">10 patients: 3 Male/7 Female, Age range: 18&#x02013;57 years</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Positive for anti-CHIKV IgG (ELISA)</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">8 patients </td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">none</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Complete blood count, comprehensive metabolic panel, ESR, CRP, CCP, RF, ANA, CyTOF analysis of PBMCs</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Acute symptoms: fever, rash, headache, symmetric polyarthritis. Chronic symptoms: persistent arthritis (hands, feet, ankles), morning stiffness, pain, joint swelling</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">8 of 10 patients developed RA; immune profile (T cells, NK cells) was similar to RA, highlighting diagnostic challenges.</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Moderate <sup>c</sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Tritsch et al., 2020 [<xref rid="B21-tropicalmed-10-00054" ref-type="bibr">21</xref>], Colombia</td><td align="left" valign="middle" rowspan="1" colspan="1">Cross-sectional follow-up</td><td align="left" valign="middle" rowspan="1" colspan="1">120 patients: 17 Male/103 Female, Age Mean: 51 &#x000b1; 14 years</td><td align="left" valign="middle" rowspan="1" colspan="1">Clinically confirmed CHIKV, serologically confirmed (IgM and IgG)</td><td align="left" valign="middle" rowspan="1" colspan="1">2 patients </td><td align="left" valign="middle" rowspan="1" colspan="1">none</td><td align="left" valign="middle" rowspan="1" colspan="1">EQ-5D questionnaire, joint count, global pain score</td><td align="left" valign="middle" rowspan="1" colspan="1">54% of patients reported persistent joint pain 40 months post-infection; most common type of pain was relapsing-remitting; stiffness was reported by 75% of patients post-immobility.</td><td align="left" valign="middle" rowspan="1" colspan="1">Around 1 in 8 patients had persistent joint pain 3 years after infection. Over half of patients with joint pain experienced relapsing-remitting symptoms.</td><td align="left" valign="middle" rowspan="1" colspan="1">Moderate <sup>a</sup></td></tr><tr><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pollett et al., 2023 [<xref rid="B23-tropicalmed-10-00054" ref-type="bibr">23</xref>], USA</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Retrospective cohort study</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">195 patients: 103 Male/92 Female; Median age: 42 years [IQR 31&#x02013;54]</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Diagnosed using RT-PCR or serological testing (IgM/IgG)</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">7 patients </td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Matched non-CHIKV controls (1:4 ratio) based on age, gender, beneficiary status, and healthcare encounter date</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Incident rheumatic diagnoses, healthcare utilization, conditional logistic regression models</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Acute symptoms included fever, polyarthralgia, backache, headache, fatigue; post-CHIKV rheumatological sequelae such as arthralgia, polyarthritis, polymyalgia rheumatica, and RA were observed.</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CHIKV infection was associated with a significantly higher risk of developing rheumatological sequelae (aOR = 1.911, <italic toggle="yes">p</italic> = 0.002). 32.3% of CHIKV cases had incident rheumatic diagnoses compared to 20.0% of controls. No significant demographic, clinical, or occupational predictors were identified for rheumatic complications.</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Low <sup>b</sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Bouquillard et al., 2017 [<xref rid="B24-tropicalmed-10-00054" ref-type="bibr">24</xref>], France</td><td align="left" valign="middle" rowspan="1" colspan="1">Prospective observational cohort study</td><td align="left" valign="middle" rowspan="1" colspan="1">307 patients: 52 male/255 female; Mean age: 54 &#x000b1; 12.6 years (24&#x02013;87)</td><td align="left" valign="middle" rowspan="1" colspan="1">Serology (IgM and/or IgG positive)</td><td align="left" valign="middle" rowspan="1" colspan="1">13 patients </td><td align="left" valign="middle" rowspan="1" colspan="1">Patients with serological confirmation vs. clinical diagnosis; evolution of symptoms under different treatments.</td><td align="left" valign="middle" rowspan="1" colspan="1">HAQ score, VAS pain, synovial fluid analysis</td><td align="left" valign="middle" rowspan="1" colspan="1">Chronic joint pain persisted in 83.1% of patients after 32 months; synovitis observed in 64.2%, primarily affecting wrists, fingers, and ankles. Symptoms included fever, arthralgia, swollen joints, myalgia, rash, headache.</td><td align="left" valign="middle" rowspan="1" colspan="1">83.1% of patients reported persistent joint pain; 4% developed RA post-infection; significant functional impairment was moderate, with a mean HAQ score of 0.44 &#x000b1; 0.5.</td><td align="left" valign="middle" rowspan="1" colspan="1">Moderate <sup>b</sup></td></tr><tr><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Bouquillard and Combe, 2009 [<xref rid="B32-tropicalmed-10-00054" ref-type="bibr">32</xref>], France</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Prospective case series</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">21 patients: 13 female/8 male, Mean age: 57 &#x000b1; 12 years</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Serology confirmed (IgM and IgG antibodies)</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">21 patients</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">none</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">ESR, CRP, RF, anti-CCP, radiographs, MRI</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Persistent arthritis from onset of CHIKV infection; 18 with symmetric polyarthritis, 3 with oligoarthritis; high ESR, positive RF in 57.1%, anti-CCP in 28.6%, erosions in hands/feet.</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Severe outcomes in most cases; radiological evidence of joint damage in 80% of patients; 6 required TNF blockers due to inadequate response to methotrexate; suggests viral role in RA initiation.</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Moderate <sup>c</sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Manimunda et al., 2010 [<xref rid="B25-tropicalmed-10-00054" ref-type="bibr">25</xref>], India</td><td align="left" valign="middle" rowspan="1" colspan="1">Prospective observational cohort study</td><td align="left" valign="middle" rowspan="1" colspan="1">203 patients: 96 Male/107 Female; Median age: 35 years [IQR 25&#x02013;44]</td><td align="left" valign="middle" rowspan="1" colspan="1">Serologically confirmed (IgM antibody ELISA)</td><td align="left" valign="middle" rowspan="1" colspan="1">34 patients</td><td align="left" valign="middle" rowspan="1" colspan="1">None </td><td align="left" valign="middle" rowspan="1" colspan="1">ESR, X-ray, MRI, anti-CCP, RF</td><td align="left" valign="middle" rowspan="1" colspan="1">Acute symptoms: fever, joint pain, rash; chronic symptoms at 10 months: joint pain, swelling, fatigue; X-ray and MRI showed joint effusion, bony erosion, marrow edema, synovial thickening, tendinitis, tenosynovitis.</td><td align="left" valign="middle" rowspan="1" colspan="1">Chronic arthritis confirmed in 75% of patients at 10 months; 36% met ACR criteria for RA; joint erosion observed in some patients, proving that CHIK arthritis is chronic inflammatory erosive arthritis.</td><td align="left" valign="middle" rowspan="1" colspan="1">Low <sup>b</sup></td></tr><tr><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Segura-Charry et al., 2021 [<xref rid="B28-tropicalmed-10-00054" ref-type="bibr">28</xref>], Colombia</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Retrospective observational longitudinal study</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">410 patients: 47 Male/363 Female; Mean age: 57.3 &#x000b1; 11.7 years</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical and serological confirmation (IgG)</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">87 patients </td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">none</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical assessment by expert rheumatologists, paraclinical tests (autoantibodies, acute phase reagents), imaging studies, use of ACR/EULAR and ASAS criteria</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Persistent musculoskeletal and joint symptoms for more than 3 months, with 46.3% non-inflammatory arthralgias, 21.9% post-viral polyarthritis, 20.3% de novo RA</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">20.3% developed RA post-CHIKV, 58.6% seropositive for RA; significant need for advanced pharmacological measures, including biological therapy in some cases.</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Low <sup>b</sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Javelle et al., 2015 [<xref rid="B33-tropicalmed-10-00054" ref-type="bibr">33</xref>], Reunion Island</td><td align="left" valign="middle" rowspan="1" colspan="1">Retrospective case series</td><td align="left" valign="middle" rowspan="1" colspan="1">159 patients: 40 male/119 female; Median age: 51 years (range 16&#x02013;80)</td><td align="left" valign="middle" rowspan="1" colspan="1">Clinical and serological confirmation (RT-PCR, IgM, IgG)</td><td align="left" valign="middle" rowspan="1" colspan="1">40 patients </td><td align="left" valign="middle" rowspan="1" colspan="1">none</td><td align="left" valign="middle" rowspan="1" colspan="1">Time to first consultation, response to methotrexate (MTX), need for additional treatments</td><td align="left" valign="middle" rowspan="1" colspan="1">Persistent musculoskeletal pain, polyarthritis, spondyloarthritis; median delay of 2 years from infection to rheumatologist consultation; 66% had prolonged acute infection </td><td align="left" valign="middle" rowspan="1" colspan="1">MTX was effective in 75% of treated patients; hydroxychloroquine and ribavirin were ineffective; need for specific management guidelines to prevent progression to chronic disease.</td><td align="left" valign="middle" rowspan="1" colspan="1">Low <sup>c</sup></td></tr><tr><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Amaral et al., 2018 [<xref rid="B34-tropicalmed-10-00054" ref-type="bibr">34</xref>], Brazil</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Retrospective case series</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">50 patients: 4 Male/46 Female; Mean age: 61.9 &#x000b1; 12.5 years</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical and serological confirmation (IgG serology by ELISA)</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">11 patients </td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">none</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">VAS, Swollen and Tender Joint Count</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Chronic symptoms persisted for more than 12 weeks post-infection; polyarthralgia, polyarthritis, morning stiffness, and tenosynovitis reported in many patients.</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Methotrexate significantly reduced pain and disease activity; rapid reduction in VAS pain scores from baseline to 4 and 8 weeks; well-tolerated with no serious adverse events.</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Moderate <sup>c</sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Rodriguez-Morales et al., 2016 [<xref rid="B36-tropicalmed-10-00054" ref-type="bibr">36</xref>], Colombia</td><td align="left" valign="middle" rowspan="1" colspan="1">Retrospective observational cohort study</td><td align="left" valign="middle" rowspan="1" colspan="1">283 patients: 110 male (39%), 173 female (61%); Median age: 29 years (IQR 17&#x02013;42)</td><td align="left" valign="middle" rowspan="1" colspan="1">Clinical confirmation and serological testing (IgM/IgG antibodies)</td><td align="left" valign="middle" rowspan="1" colspan="1">152 patients </td><td align="left" valign="middle" rowspan="1" colspan="1">None</td><td align="left" valign="middle" rowspan="1" colspan="1">Relative risk (RR), Kaplan-Meier survival curves, Cox regression</td><td align="left" valign="middle" rowspan="1" colspan="1">Persistent polyarthralgia (pCHIK-CPA) with symptoms including morning stiffness (49.5%), joint edema (40.6%), and joint redness (16.6%); higher prevalence of symptoms in patients &#x0003e; 40 years and females; significant persistence of symptoms up to 26 weeks.</td><td align="left" valign="middle" rowspan="1" colspan="1">53.7% of patients developed RA (pCHIK-CPA); more common in patients &#x0003e; 40 years old (69.7%) compared to &#x02264;40 years old (47.8%); higher prevalence in females (59.5%) than males (44.5%); 19.4% of patients required ongoing medical care for persistent symptoms</td><td align="left" valign="middle" rowspan="1" colspan="1">Low <sup>b</sup></td></tr><tr><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ravindran and Alias, 2016 [<xref rid="B35-tropicalmed-10-00054" ref-type="bibr">35</xref>], India</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Randomized controlled open-label clinical trial</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">72 patients: 37 in combination therapy, 35 in monotherapy; Combination group: 4 male, 33 female; Monotherapy group: 5 male, 30 female; Age Mean &#x000b1; SD: Combination: 54.05 &#x000b1; 6.67, Monotherapy: 56.6 &#x000b1; 7.64</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Serologically confirmed (virus-specific IgM antibodies)</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">12 patients </td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Combination therapy (MTX, SSZ, and HCQ) vs. HCQ monotherapy</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">DAS28, HAQ, VAS</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Persistent arthritis for &#x0003e;1 year post-CHIKV infection; symptoms included swollen joints, tenderness, and high disease activity. Both groups were previously on HCQ with active disease; assessed for response to combination therapy versus monotherapy.</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Combination therapy significantly improved DAS28, HAQ, and VAS compared to monotherapy; 85% achieved EULAR good response in combination group vs. 14% in monotherapy group; combination therapy more effective in achieving low disease activity and reducing pain.</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Some concerns <sup>d</sup></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Paul et al., 2011 [<xref rid="B26-tropicalmed-10-00054" ref-type="bibr">26</xref>], India</td><td align="left" valign="middle" rowspan="1" colspan="1">Prospective observational cohort study</td><td align="left" valign="middle" rowspan="1" colspan="1">150 patients: 40 male/110 female; Age range: 20&#x02013;60 years</td><td align="left" valign="middle" rowspan="1" colspan="1">Serological confirmation (IgM capture ELISA)</td><td align="left" valign="middle" rowspan="1" colspan="1">5 patients</td><td align="left" valign="middle" rowspan="1" colspan="1">None</td><td align="left" valign="middle" rowspan="1" colspan="1">Symptom duration, response to antimalarials and steroids</td><td align="left" valign="middle" rowspan="1" colspan="1">100% of patients had arthralgia, 78% had arthritis, 22% had persistent symptoms beyond one year; common symptoms included fever, rash, and morning stiffness; antimalarials and short courses of steroids were partially effective in some cases.</td><td align="left" valign="middle" rowspan="1" colspan="1">22% developed chronic symptoms; 5% of patients developed RA after CHIKV infection; RA cases had anti-CCP positivity; synovial biopsies showed chronic inflammation.</td><td align="left" valign="middle" rowspan="1" colspan="1">Low <sup>b</sup></td></tr><tr><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mathew et al., 2011 [<xref rid="B27-tropicalmed-10-00054" ref-type="bibr">27</xref>], India</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Retrospective observational cohort study</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">437 patients: 124 male/313 female; Mean age: 48.37 &#x000b1; 13.62 years</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical confirmation and serology (IgM antibodies)</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">6 patients</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">None</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pain site assessment, ACR criteria for rheumatic diseases, lab tests (ESR, CRP, RF, anti-CCP), musculoskeletal ultrasound</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Common pain sites: knee (83.3%), ankle (63.2%), lower back (49.4%); 57% had post-viral polyarthralgia, 22% had post-viral polyarthritis.</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">8.3% incidence of RMSK pain in na&#x000ef;ve group; higher prevalence of chronic rheumatic disorders post-CHIKV, including RA and seronegative spondyloarthritis.</td><td align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Low <sup>b</sup></td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Guillot et al., 2020 [<xref rid="B30-tropicalmed-10-00054" ref-type="bibr">30</xref>], Reunion Island</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective observational cohort study</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">159 patients: Gender distribution not fully specified; Age data not provided</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical confirmation and serological testing (IgM/IgG antibodies)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40 patients</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">none</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Clinical examination, autoantibodies (ACPA, RF, ANA), radiographic evaluations, DAS28 score, BASDAI score</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inflammatory joint symptoms persisted after 13 years; higher prevalence of positive autoantibodies (antinuclear or ACPA) without seroconversion, and radiographic joint damage in a subgroup</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23.3% of patients initially diagnosed with CHIK-related inflammatory joint symptoms continued to have symptoms after 13 years; long-term IgM positivity and radiographic damage were more frequent in the persistence group.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low <sup>b</sup></td></tr></tbody></table><table-wrap-foot><fn><p>ANA: antinuclear antibody; BASDAI: bath ankylosing spondylitis disease activity index; CCP: cyclic citrullinated peptide; CHIKV: chikungunya virus; CRP: C-reactive protein; CyTOF: cytometry by time-of-flight; DAS28: Disease Activity Score in 28 joints; EQ-5D-5L: The EuroQol 5-Dimension 5-level; ESR: erythrocyte sedimentation rate; HAQ: Health Assessment Questionnaire; MRI: magnetic resonance imaging; MSQ: musculoskeletal stiffness questionnaire; OA: osteoarthritis; PBMCs: peripheral blood mononuclear cells; RA: rheumatoid arthritis; RF: rheumatoid factor; RMSK: rheumatic-musculoskeletal; RT-qPCR: reverse transcription-quantitative (polymerase chain reaction); SpA: spondyloarthritis; TNF: tumor necrosis factor; VAS: visual analogue scale. <sup>a</sup>: Based on The Joanna Briggs Institute Critical Appraisal tool for cross-sectional analysis studies. <sup>b</sup>: Based on The Joanna Briggs Institute Critical Appraisal tool for cohort studies. <sup>c</sup>: Based on the Newcastle&#x02013;Ottawa Scale (NOS) tool for case series. <sup>d</sup>: Based on RoB 2.0 tool for randomized trials.</p></fn></table-wrap-foot></table-wrap></floats-group></article>